236 related articles for article (PubMed ID: 20882037)
1. Expression of the stem cell markers nestin and CD133 on circulating melanoma cells.
Fusi A; Reichelt U; Busse A; Ochsenreither S; Rietz A; Maisel M; Keilholz U
J Invest Dermatol; 2011 Feb; 131(2):487-94. PubMed ID: 20882037
[TBL] [Abstract][Full Text] [Related]
2. Co-expression of putative cancer stem cell markers, CD133 and Nestin, in skin tumors.
Sabet MN; Rakhshan A; Erfani E; Madjd Z
Asian Pac J Cancer Prev; 2014; 15(19):8161-9. PubMed ID: 25339000
[TBL] [Abstract][Full Text] [Related]
3. CD10 expression by melanoma cells is associated with aggressive behavior in vitro and predicts rapid metastatic progression in humans.
Thomas-Pfaab M; Annereau JP; Munsch C; Guilbaud N; Garrido I; Paul C; Brousset P; Lamant L; Meyer N
J Dermatol Sci; 2013 Feb; 69(2):105-13. PubMed ID: 23219141
[TBL] [Abstract][Full Text] [Related]
4. Immuno-expression of human melanoma stem cell markers in tissues at different stages of the disease.
Sharma BK; Manglik V; Elias EG
J Surg Res; 2010 Sep; 163(1):e11-5. PubMed ID: 20638684
[TBL] [Abstract][Full Text] [Related]
5. The stem cell marker nestin predicts poor prognosis in human melanoma.
Piras F; Perra MT; Murtas D; Minerba L; Floris C; Maxia C; Demurtas P; Ugalde J; Ribatti D; Sirigu P
Oncol Rep; 2010 Jan; 23(1):17-24. PubMed ID: 19956860
[TBL] [Abstract][Full Text] [Related]
6. Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer.
Qin Q; Sun Y; Fei M; Zhang J; Jia Y; Gu M; Xia R; Chen S; Deng A
Neoplasma; 2012; 59(3):310-5. PubMed ID: 22296500
[TBL] [Abstract][Full Text] [Related]
7. Expression of the stem cell markers CD133 and nestin in pancreatic ductal adenocarcinoma and clinical relevance.
Kim HS; Yoo SY; Kim KT; Park JT; Kim HJ; Kim JC
Int J Clin Exp Pathol; 2012; 5(8):754-61. PubMed ID: 23071857
[TBL] [Abstract][Full Text] [Related]
8. Expression of CD133 and other putative stem cell markers in uveal melanoma.
Thill M; Berna MJ; Grierson R; Reinhart I; Voelkel T; Piechaczek C; Galambos P; Jager MJ; Richard G; Lange C; Gehling UM
Melanoma Res; 2011 Oct; 21(5):405-16. PubMed ID: 21900792
[TBL] [Abstract][Full Text] [Related]
9. CD133 expression and identification of CD133/nestin positive cells in rhabdomyosarcomas and rhabdomyosarcoma cell lines.
Sana J; Zambo I; Skoda J; Neradil J; Chlapek P; Hermanova M; Mudry P; Vasikova A; Zitterbart K; Hampl A; Sterba J; Veselska R
Anal Cell Pathol (Amst); 2011; 34(6):303-18. PubMed ID: 22156015
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of stem cell markers in malignant melanoma.
Klein WM; Wu BP; Zhao S; Wu H; Klein-Szanto AJ; Tahan SR
Mod Pathol; 2007 Jan; 20(1):102-7. PubMed ID: 17143262
[TBL] [Abstract][Full Text] [Related]
11. [Correlative study of distribution of brain tumor stem cell with micro-vascular system].
Li MW; Niu CS
Zhonghua Yi Xue Za Zhi; 2010 Feb; 90(5):305-9. PubMed ID: 20368050
[TBL] [Abstract][Full Text] [Related]
12. The pathological characteristics of glioma stem cell niches.
He H; Li MW; Niu CS
J Clin Neurosci; 2012 Jan; 19(1):121-7. PubMed ID: 22178090
[TBL] [Abstract][Full Text] [Related]
13. Expression of neural stem cell surface marker CD133 in balloon cells of human focal cortical dysplasia.
Ying Z; Gonzalez-Martinez J; Tilelli C; Bingaman W; Najm I
Epilepsia; 2005 Nov; 46(11):1716-23. PubMed ID: 16302851
[TBL] [Abstract][Full Text] [Related]
14. Nestin and vimentin colocalization affects the subcellular location of glucocorticoid receptor in cutaneous melanoma.
Lai S; Piras F; Spiga S; Perra MT; Minerba L; Piga M; Mura E; Murtas D; Demurtas P; Corrias M; Maxia C; Ferreli C; Sirigu P
Histopathology; 2013 Feb; 62(3):487-98. PubMed ID: 23072594
[TBL] [Abstract][Full Text] [Related]
15. CD133+ and nestin+ tumor-initiating cells dominate in N29 and N32 experimental gliomas.
Bexell D; Gunnarsson S; Siesjö P; Bengzon J; Darabi A
Int J Cancer; 2009 Jul; 125(1):15-22. PubMed ID: 19291792
[TBL] [Abstract][Full Text] [Related]
16. Clonal dominance of CD133+ subset population as risk factor in tumor progression and disease recurrence of human cutaneous melanoma.
Sharma BK; Manglik V; O'Connell M; Weeraratna A; McCarron EC; Broussard JN; Divito KA; Simbulan-Rosenthal CM; Rosenthal DS; Zapas JL
Int J Oncol; 2012 Nov; 41(5):1570-6. PubMed ID: 22922842
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
Dahlrot RH
Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
[TBL] [Abstract][Full Text] [Related]
18. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients.
Zhang M; Song T; Yang L; Chen R; Wu L; Yang Z; Fang J
J Exp Clin Cancer Res; 2008 Dec; 27(1):85. PubMed ID: 19108713
[TBL] [Abstract][Full Text] [Related]
19. What is the clinical value of cancer stem cell markers in gliomas?
Dahlrot RH; Hermansen SK; Hansen S; Kristensen BW
Int J Clin Exp Pathol; 2013; 6(3):334-48. PubMed ID: 23412423
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of the hair follicle stem cell marker nestin in patients with malignant melanoma.
Tanabe K; Amoh Y; Kanoh M; Takasu H; Sakai N; Sato Y; Katsuoka K
Eur J Dermatol; 2010; 20(3):283-8. PubMed ID: 20156773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
